Serum Glial Fibrillary Acidic Protein Dynamics, Disease Progression, and Therapy Response in Multiple Sclerosis

胶质纤维酸性蛋白 多发性硬化 医学 队列 内科学 队列研究 胃肠病学 疾病 扩大残疾状况量表 观察研究 前瞻性队列研究 病理 生物标志物 免疫学 中枢神经系统疾病 临床终点 外科 纵向研究 临床孤立综合征 肿瘤科
作者
Maximilian Einsiedler,Sofia Sandgren,Sabine A. Schaedelin,Kiarra Ning,Aleksandra Maleska Maceski,Johanna Oechtering,Christian Cordano,Lester Melie‐García,Jeffrey Marc Gelfand,Alessandro Cagol,Roland G. Henry,Sebastian Finkener,Patrice H. Lalive,Stefanie Müller,Caroline Pot,Amandine Mathias,Renaud Du Pasquier,Robert Hoepner,Andrew Chan,Giulio Disanto
出处
期刊:JAMA Neurology [American Medical Association]
卷期号:83 (9): 894-894 被引量:1
标识
DOI:10.1001/jamaneurol.2026.2500
摘要

Importance: Capturing individual multiple sclerosis (MS) progression is difficult; few studies have evaluated glial fibrillary acidic protein (GFAP) in large longitudinal cohorts with independent validation. Objective: To investigate whether serum GFAP levels and treatment-related changes are associated with future progression independent of relapse activity (PIRA). Design, Setting, and Participants: This was a prospective observational study using 2 large MS cohorts: the Swiss MS Cohort (SMSC; initiated in June 2012; data extraction September 22, 2025) and the Expression, Proteomics, Imaging, Clinical study (EPIC; initiated in July 2004; data extraction February 21, 2024). The study took place at tertiary MS centers (8 for SMSC and 1 for EPIC). A total of 2329 persons with MS from both cohorts with at least 1 available time point with neurofilament light chain (NfL) and GFAP measurements were included (overall 18 629 measurements). Exposures: Clinical data and NfL and GFAP z scores, collected and calculated every 6 or 12 months. Main Outcomes and Measures: Risk of future PIRA, defined as Expanded Disability Status Scale score worsening confirmed after 6 or more months without relapses (in SMSC), or a composite additionally including greater than 20% worsening in the 9-hole peg test or timed 25-ft walk test (in EPIC). Results: The SMSC and EPIC cohorts consisted of 1709 (13 375 samples; median [IQR] follow-up, 6.9 [2.5-10.7] years and age, 40.6 [32.1-50.1] years; 1128 [66.0%] female) and 620 (5254 samples; median [IQR] follow-up, 13.1 [9.4-14.0] years and age, 42.0 [35.0-50.0] years; 432 [69.7%] female) persons with MS, respectively. Consistent with prior work, high NfL was associated with relapse risk within the next year, whereas high GFAP was associated with long-term PIRA risk. In addition, elevated GFAP (z score >1.0 [84th percentile]) was associated with an average 40% higher hazard of short-term PIRA in the subsequent visit interval (SMSC: median [IQR] 346 [190-375] days; hazard ratio [HR], 1.45, 95% CI, 1.21-1.75; P < .001; EPIC: 385 [355-518] days; HR, 1.36; 95% CI, 1.07-1.71; P = .01). GFAP-based cohort enrichment in clinical trials targeting PIRA as an end point could reduce sample size by approximately 20%. Further, in SMSC, every yearly GFAP z score unit reduction during the first 2 years receiving fingolimod or B-cell-depleting therapy was associated with a lower risk of subsequent PIRA (54% risk reduction; HR, 0.46; 95% CI, 0.26-0.84; P = .01 and 67% risk reduction; HR, 0.33; 95% CI, 0.18-0.61; P < .001), respectively. Conclusions and Relevance: In this cohort study, elevated GFAP was associated with a higher risk of PIRA, while treatment-associated reductions were associated with a lower PIRA risk. Together, these results suggest that serum GFAP may serve as a biomarker for personalized risk stratification and treatment monitoring and as a screening tool to reduce cohort size in clinical trials targeting MS progression.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
1秒前
1秒前
赘婿的应助被蓝莓采纳,获得10
1秒前
1秒前
合适映雁完成签到 ,获得积分10
2秒前
帅气男孩发布了新的文献求助10
2秒前
兮尔发布了新的文献求助10
3秒前
lnfuture发布了新的文献求助20
3秒前
4秒前
fff222222完成签到,获得积分10
5秒前
6秒前
DailyNear发布了新的文献求助10
6秒前
今后的应助被三分之二采纳,获得10
6秒前
ChandlerZB完成签到,获得积分10
7秒前
Judy发布了新的文献求助10
7秒前
渝汐完成签到 ,获得积分10
9秒前
回望发布了新的文献求助10
10秒前
LucyHarris108发布了新的文献求助40
11秒前
风为裳完成签到,获得积分10
11秒前
zzzzzz完成签到,获得积分10
12秒前
Maestro_S的应助被xxz采纳,获得10
13秒前
小可爱喝凉开水完成签到,获得积分20
13秒前
14秒前
14秒前
14秒前
15秒前
aiyi完成签到,获得积分10
15秒前
苏苏完成签到,获得积分10
15秒前
Jasper的应助被笙笙采纳,获得10
16秒前
婠婠完成签到,获得积分10
16秒前
16秒前
简单老师的应助被33333采纳,获得10
18秒前
19秒前
风吹麦浪的应助被sss采纳,获得10
19秒前
Harry发布了新的文献求助20
20秒前
20秒前
21秒前
所所的应助被一些小事采纳,获得10
21秒前
科研黑洞完成签到,获得积分10
21秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
高分子基功能界面水蒸发材料与应用研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8177802
求助须知:如何正确求助?哪些是违规求助? 9568632
关于积分的说明 21799933
捐赠科研通 7772424
什么是DOI,文献DOI怎么找? 3432505
关于科研通互助平台的介绍 2556698
邀请新用户注册赠送积分活动 2478055